Blog Posts

Novartis and United Therapeutics File Briefs in Appeals Court in 340B Contract Pharmacy Lawsuits

Novartis and United Therapeutics filed briefs last night in a federal appeals court in Washington, D.C., backing their right to impose conditions on 340B sales.

Drug manufacturers Novartis and United Therapeutics (UT) last night urged a federal appeals court in Washington, D.C., to affirm a lower court’s November 2021 judgement that the 340B statute does not stop manufacturers from attaching any conditions to

Read More »

Important Operational Insights for Covered Entities Choosing to Access 340B ESP

SPONSORED CONTENT

Alas, after much deliberation, your covered entity has decided to submit data to 340B ESP. As you embark on this journey, you may be asking yourself: Now what?!?  

As someone who has operated a large 340B program at a DSH hospital and now has the privilege to consult many covered entities as they tackle 340B challenges, I know that making a decision and

Read More »

Congress Turns House Floor to 340B For an Hour

Rep. Abigail Spanberger (D-Va.) organized an hour's worth of testimonials for 340B Tuesday night on the U.S. House floor.

Seven U.S. representatives—five Democrats and two Republicans—lauded the 340B program on the House floor Tuesday night during an hour of speeches organized by Rep. Abigail Spanberger (D-Va.) and co-hosted by Rep. John Rose (R-Tenn.).

Read More »

FTC To Investigate PBMs’ Impact on Drug Access and Affordability

Under pressure from small pharmacies, drug makers, 340B providers, and others, the FTC agreed to "shine a light" on PBMs' business practices and their impact on pharmacies, payers, doctors, and patients.

Just months after deadlocking, the U.S. Federal Trade Commission on Tuesday voted unanimously on Tuesday to launch an investigation into pharmacy benefit managers’ business practices to assess their impact on prescription drug access and affordability.

Read More »

News Alert

Exelixis, Maker of Expensive Cancer Drugs, Is Latest Manufacturer to Impose 340B Contract Pharmacy Conditions

California-based biopharmaceutical company Exelixis is the 17th drug manufacturer to impose conditions on 340B pricing when hospitals use contract pharmacies.

Biopharmaceutical manufacturer Exelixis yesterday became the 17th drug maker to impose conditions on 340B pricing when hospitals use contract pharmacies.

Please Login or Become a Paid Subscriber to View this Content

Read More »

AstraZeneca and Sanofi Ask 340B ADR Panel to Dismiss Health Centers’ Overcharging Claims

AstraZeneca and Sanofi asked a 340B administrative dispute resolution panel to dismiss NACHC’s claims its members are being overcharged due to the companies’ 340B contract pharmacies policies.

Drug manufacturers AstraZeneca and Sanofi have asked a 340B administrative dispute resolution panel to dismiss the National Association of Community Health Centers’ claims that its members are being overcharged due to the companies’ denied or restricted 340B sales

Read More »

GlaxoSmithKline Ending Voluntary 340B Pricing on Two Orphan Drugs

GlaxoSmithKline is ending voluntary 340B pricing for rural and cancer hospitals on its blockbuster severe asthma drug Nucala and first-line advanced ovarian cancer drug Zejula.

In a blow to rural and cancer hospitals, U.K. drug manufacturer GlaxoSmithKline (GSK) is ending voluntary 340B pricing for them on its blockbuster severe asthma drug Nucala and first-line advanced ovarian cancer drug Zejula.

Read More »

In a Move to Expand its Specialty Pharmacy Services, CPS Acquires Trellis Rx

CPS Chairman & CEO Frank Segrave (left) says his company's acquisition of Trellis Rx "helps us to deliver a broader range of offerings and flexibility across our inpatient and outpatient businesses." Trellis co-founder and CEO Andy Maurer (right) says the companies "complement each other and together, we can create a more diverse offering across inpatient, outpatient and specialty pharmacy settings for health and hospital systems serving communities of all sizes."

340B pharmacy and health-system services provider CPS Solutions, based in Dublin, Ohio, has announced it had acquired specialty pharmacy services company Trellis Rx, headquartered in Atlanta, Ga.

Please Login or Become a Paid Subscriber

Read More »

Generic-drug Maker e5 Pharma Offering Refunds for 340B Overcharges

e5 Pharma is giving 340B covered entities refunds for overcharges on six NDCs of the barbiturate phenobarbital during Q1 2021.

Generic drug maker e5 Pharma is giving 340B covered entities refunds for overcharges on six NDCs of the barbiturate phenobarbital during Q1 2021, according to a public notice on the U.S. Health Resources and Services Administration (HRSA) website.

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report